| Drug Name: | Progesterone (57-83-0) |
|---|---|
| PubChem ID: | 5994 |
| SMILES: | CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C |
| InchiKey: | RJKFOVLPORLFTN-LEKSSAKUSA-N |
| Therapeutic Category: | Hormones, Progestins |
| Molecular Weight (dalton) | : | 314.469 |
| LogP | : | 4.7235 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 34.14 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Increase Luteal Cell Progesterone Accumulation | Retinol-binding protein cellular (P09455) | Retinoids increase luteal cell progesterone accumulation [ ADR Type 1 ] | Lack of difference between retinoic acid and retinol in stimulating progesterone production by luteinizing granulosa cells in vitro |
| Luteinizing Hormone Surge | Angiotensinogen precursor (P01019) | Dynamic changes in hypothalamic angiotensin II levels and release in association with progesterone-induced luteinizing hormone surge,which is associated with progesterone-induced luteinizing hormone surge [ ADR Type 1 ] | Dynamic changes in hypothalamic angiotensin II levels and release in association with progesterone-induced luteinizing hormone surge |
| Luteinizing Hormone Surge | LHRH (P00027) | This is an experimental paradigm that reliably evokes dynamic changes in hypothalamic LHRH levels in association with LH hypersecretion,which is association with progesterone-induced luteinizing hormone surge. [ ADR Type 1 ] | Dynamic changes in hypothalamic angiotensin II levels and release in association with progesterone-induced luteinizing hormone surge |
| Luteinizing Hormone Surge | luteinizing hormone (P22888) | This is an experimental paradigm that reliably evokes dynamic changes in hypothalamic LHRH levels in association with LH hypersecretion@which is association with progesterone-induced luteinizing hormone surge. [ ADR Type 1 ] | Dynamic changes in hypothalamic angiotensin II levels and release in association with progesterone-induced luteinizing hormone surge |
| Oocyte Maturation | Mitogen-activated protein kinase(ERK) (P28482) | The increase in Raf-1 activity was concurrent with an elevation in the activity of mitogen-activated protein (MAP) kinase@which leads to progesterone-induced oocyte maturation [ ADR Type 1 ] | Raf-1 protein kinase is important for progesterone-induced Xenopus oocyte maturation and acts downstream of mos |
| Oocyte Maturation | Raf-1 serine/threonine protein kinase (P31750) | Raf-1 enzymatic activity and phosphorylation (reflected by a mobility shift on sodium dodecyl sulfate gels) were increased in oocytes following progesterone stimulation@which leads to progesterone-induced oocyte maturation. [ ADR Type 1 ] | Raf-1 protein kinase is important for progesterone-induced Xenopus oocyte maturation and acts downstream of mos |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category